Anavatos Bio provides an automated biomanufacturing platform for producing custom-designed proteins. This integrated, plug-and-play solution is tailored for small-batch manufacturing, offering faster turnaround times and reduced costs for pre-clinical and Phase I research programs. The company facilitates seamless technology transfer for representative biologics manufacturing at smaller scales.
Funding
Funding not disclosed
Founders
Product
Problem
Early‑phase research programs often require custom‑designed proteins in limited quantities, but conventional biomanufacturing facilities are optimized for large‑scale production, leading to long lead times, high per‑gram costs, and complex technology transfer processes.
Solution
Anavatos Bio delivers an automated, plug‑and‑play biomanufacturing platform that streamlines small‑batch protein production from gene construct to formulated biologic. The system integrates upstream expression, downstream purification, and formulation steps within a single, modular hardware suite, enabling end‑to‑end runs without manual reconfiguration. By standardizing the workflow on industry‑grade consumables, the platform reduces cycle time to roughly eight weeks and cuts material and labor costs by an order of magnitude compared with traditional contract manufacturing. Seamless technology transfer is built into the software, allowing researchers to move from design to test material quickly while maintaining GMP‑compatible traceability. The solution is purpose‑built for pre‑clinical and Phase I biologics, providing reliable batch‑to‑batch consistency at scales appropriate for early‑stage studies.
Target Audience
Primary customers are biotech R&D laboratories, contract research organizations, and early‑phase pharmaceutical programs that need custom protein therapeutics or research reagents in small, fast‑turnaround batches.
Features
- Fully automated upstream expression and downstream purification modules with integrated process control
- Modular hardware that can be reconfigured for different host systems (E. coli, yeast, CHO) without extensive re‑engineering
- End‑to‑end software suite that manages batch recipes, real‑time monitoring, and data logging for regulatory compliance
- Use of GMP‑grade raw materials and single‑use disposable flow paths to minimize cross‑contamination risk
- Rapid technology transfer workflow that translates design files into production runs in under 48 hours
- Scalable output from 10 mg to 100 mg of formulated protein per batch, suitable for early‑phase studies
- Cloud‑connected batch tracking and analytics dashboard for inventory management and quality oversight
- Plug‑and‑play integration with existing laboratory LIMS/EHR systems via standard APIs